Golfer247 - The latest news and products from the world of golf
Main Menu | News By Date | News By Supplier | News By Category | About Us
 

SCIENTISTS TO DEVELOP NEW STRATEGIES FOR VACCINATION THAT CAN BETTER PROTECT ORGAN TRANSPLANT RECIPIENTS
09 February 2007 - Emory University

Scientists at Emory University will use a $10 million grant from the National Institutes of Health to develop new strategies for vaccination that can better protect organ transplant recipients and other immune-suppressed patients from infectious disease threats.

Scientists at Emory University will use a $10 million grant from the National Institutes of Health to develop new strategies for vaccination that can better protect organ transplant recipients and other immune-suppressed patients from infectious disease threats.

The five-year grant from the National Institute of Allergy and Infectious Diseases was awarded to scientists in the Emory Transplant Center, the Emory Vaccine Center and the Yerkes National Primate Research Center. Christian P. Larsen, MD, PhD, director of the Emory Transplant Center, is principal investigator of the NIH grant and Rafi Ahmed, PhD, director of the Emory Vaccine Center, is program director.

Despite vast improvements in the prevention of infectious diseases over the past century, many individuals, including organ transplant recipients, are either unable to receive certain kinds of vaccinations or may not derive the same level of protection from vaccines. Transplant recipients must take drugs to help prevent rejection of their transplanted organs, but these drugs suppress their immune systems and leave them vulnerable to infection. While several vaccines are appropriate and recommended for immune-suppressed patients, it is known that vaccines are less effective in these vulnerable populations. However, emerging knowledge from basic immunology research is giving scientists new insights into the precise effects of vaccines on the immune system and how to improve vaccine effectiveness for these patients.

The challenge of new emerging infectious diseases, the threat of bioterrorism, and the ever-present possibility of pandemic influenza have highlighted the need for new strategies to protect immunocompromised groups from infectious diseases. The new NIH-funded research program should provide new knowledge about the biology of existing and newly developed immunosuppressive drugs for transplant patients and novel ideas about how to improve immune responses in these patients while at the same time protecting their transplanted organs from rejection.

"Thousands of patients have benefited from organ transplantation," says Dr. Larsen, "but a major challenge remains, the lifelong immunosuppressive drugs these patients must take and the effect the drugs have on overall health and the ability to defend against infections. The growing number of patients who have received transplanted organs and the major threats of global infectious diseases make it imperative that we develop effective ways of protecting these patients from natural or human-caused disease outbreaks."

Broad recommendations that either rule out vaccination for organ transplant recipients or recommend only certain kinds of vaccines do not take into account new developments in transplant drugs or new knowledge about vaccines and immunity, says Dr. Larsen. The recommendations also do not account for individual differences in immune response or changes over time.

"Part of our goal is to develop new strategies that could protect transplant patients from potential bioterrorism agents," says Dr. Ahmed. "Although studies have not been done in transplant patients to test the current smallpox vaccination based on vaccinia virus, individuals with defects in T cell immunity are known to have very serious side effects from vaccination. We believe modified vaccinia Ankara vaccine, which is based on a related poxvirus, may be a safer alternative for these patients."

Dr. Larsen, his colleague Thomas Pearson, MD, PhD, director of the kidney transplant program at Emory University, and their research team have worked for the past decade on developing new immune strategies and new kinds of drugs that would be less toxic for transplant patients. Dr. Ahmed, an internationally recognized expert in the mechanisms of immune memory, has been a major collaborator on immune studies with Emory's transplant team.

http://www.emory.edu

About: Emory University
Emory University is home to nine major academic divisions, numerous centres for advanced study, and a host of prestigious affiliated institutions. In addition to Emory College, the University encompasses a graduate school of arts and sciences; professional schools of medicine, theology, law, nursing, public health, and business; and Oxford College, a two-year undergraduate division on the original campus of Emory in Oxford, Ga.

Emory was founded at Oxford by the Methodist Church in 1836. Led by President James W. Wagner, an award-winning teacher and scholar, the University has 11,300 students and 2,500 faculty members who represent all regions of the United States and more than 100 foreign nations.

Emory University is known for its demanding academics, outstanding undergraduate college of arts and sciences, highly ranked professional schools and state-of-the-art research facilities. For more than a decade Emory has been named one of the country's top 25 national universities by U.S. News & World Report. In addition to its nine schools, the university encompasses The Carter Center, Yerkes National Primate Research Center and Emory Healthcare, a comprehensive metropolitan health care system.


More News:
  • For February 2007
  • From Emory University
  • For University

 

©2008 New Materials International